Koontz Center

The Saint Luke's Koontz Center for Advanced Breast Cancer is devoted exclusively to improving outcomes & quality of life for metastatic breast cancer patients.

[Koontz Center @KoontzCenter]

Congratulations to Rich Liekweg, BJC Health System CEO, who announced his plans to retire on October 1, 2025.

BJC is pleased to announce that Nick Barto, current BJC Health System President, will succeed Rich as President and CEO of BJC Health System: https://t.co/8y5kuBrVeK

[Koontz Center @KoontzCenter]

Robin, a patient with metastatic breast cancer, and her daughter, Bethany, recently completed a 5K walk/run at Arrowhead Stadium! #BreastCancerAwarenessMonth

[Koontz Center @KoontzCenter]

Are you up-to-date on this breast cancer subtype? Check your knowledge with this quick quiz: https://t.co/csKTRzUhj8

[Koontz Center @KoontzCenter]

Saint Luke’s Hospital Koontz Center for Advanced Breast Cancer has a singular goal: Improving outcomes and quality of life for women and men with advanced (metastatic) breast cancer. Our team is dedicated to caring for the whole person. https://t.co/CMm1lB12BD

[Koontz Center @KoontzCenter]

Next-generation sequencing (NGS) and the use of prediction tools in 2 patients with a rare form of metastatic breast cancer revealed mutations in malignant phyllodes tumors, providing insight into potential therapeutic targets for these patients. https://t.co/MuH38I3uxP

[Koontz Center @KoontzCenter]

See how genomic profiling can improve outcomes in metastatic breast cancer: https://t.co/vOmohBXGHr

[Koontz Center @KoontzCenter]

Adding pyrotinib to capecitabine (Xeloda) therapy improved overall survival compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer, according to updated results from the Chinese PHOEBE trial. https://t.co/Ne6Z1BiPkW

[Koontz Center @KoontzCenter]

May the warm glow of autumn surround you as you celebrate the holiday with family and friends. Happy Thanksgiving!

[Koontz Center @KoontzCenter]

We hope you have a happy and healthy Thanksgiving! Here are a few tips for staying safe this holiday season:
-Get vaccinated against #COVID19
-Have a low-risk gathering
-Wear masks if you are not vaccinated
-Wash your hands
-Keep a safe distance
https://t.co/0IVz3bGhWf

[Koontz Center @KoontzCenter]

Gratitude is great for your health! What are some things you feel grateful for? #Thanksgiving #Mindfulness

[Koontz Center @KoontzCenter]

We have a singular goal: Improving outcomes and quality of life for women with advanced (metastatic) breast cancer. We believe in more than just treating cancer—our team is dedicated to caring for the whole woman. https://t.co/CMm1lB12BD

[Koontz Center @KoontzCenter]

The drug, dubbed ErSO, works by over-activating a normally tumor-protective pathway to make it toxic for cancer cells. https://t.co/yaSYn8NmsN

[Koontz Center @KoontzCenter]

Patients with metastatic triple-negative breast cancer being treated with leronlimab and carboplatin have experienced a decrease in cancer-associated macrophage-like cells and an increase in survival benefit. https://t.co/wD0RPaL6Pj

[Koontz Center @KoontzCenter]

The Koontz Center for Advanced Breast Cancer is the region’s first and only program dedicated to the treatment of #metastaticbreastcancer. Learn more at https://t.co/73ZYT2cKXy.

[Koontz Center @KoontzCenter]

Rhonda, a stage 4 breast cancer Koontz Center patient, and her husband Steve recently purchased a "Spreading Awareness" pink manure spreader resulting in a $50,000 donation to National Breast Cancer Foundation. Go Rhonda! #breastcancerawareness

[Koontz Center @KoontzCenter]

The FDA has granted a fast track designation to trilaciclib for use in combination with chemotherapy in patients with locally advanced or metastatic triple-negative breast cancer. https://t.co/03xropQRWt

[Koontz Center @KoontzCenter]

Food as Medicine Everyday (FAME) is a 12-week virtual nutrition education series.

Sign up for our fall series: Aug. 31 - Nov. 16.
To register call 816-932-5784. Learn more at https://t.co/BmDthS9yuI.

[Koontz Center @KoontzCenter]

We have initiated DESTINY-Breast09 to evaluate whether earlier use of ENHERTU alone or as part of a novel combination regimen may help improve outcomes for patients in the first-line metastatic setting as compared to the current standard of care. https://t.co/FhgjmHFb8H

[Koontz Center @KoontzCenter]

“Hiking is a great activity for all of us, including cancer survivors,” writes a breast cancer survivor. “As long as we can put one foot in front of the other, being out on a trail is inspirational and health-affirming.” https://t.co/5ARRVcC3hx

[Koontz Center @KoontzCenter]

This is the first trial to evaluate ENHERTU in the first-line metastatic setting in patients with HER2 positive breast cancer. https://t.co/m1LfSz2An8